Shopping Cart
- Remove All
- Your shopping cart is currently empty
HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $63 | 35 days | |
5 mg | $220 | 35 days | |
10 mg | $375 | 35 days | |
50 mg | $1,400 | 35 days |
Description | HR68, a derivative of the peroxisome proliferator-activated receptor (PPAR) agonist fenofibric acid, serves as an anticancer agent. It effectively reduces the viability of LN-229 glioblastoma cells, with an IC50 value of 1.17 µM. Notably, HR68 is capable of crossing the blood-brain barrier in temozolomide-resistant orthotopic patient-derived xenograft (PDX) mouse models of glioblastoma. |
Alias | PP21 |
Molecular Weight | 394.85 |
Formula | C22H19ClN2O3 |
Cas No. | 2454582-64-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Methanol: Soluble Ethanol: Soluble Chloroform: Soluble Acetonitrile: Soluble |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.